| Home > Articles > Published articles > Activity of ceftazidime-avibactam against clinical and isogenic laboratory Pseudomonas aeruginosa isolates expressing combinations of most relevant β-lactam resistance mechanisms |
| Date: | 2016 |
| Description: | 4 pàg. |
| Abstract: | The activity of ceftazidime-avibactam was compared with that of ceftazidime alone and meropenem against a collection of 190 Pseudomonas aeruginosa clinical isolates recovered from a multicenter study of bloodstream infections. The addition of avibactam increased ceftazidime susceptibility in the complete collection of strains (64. 7% to 91. 1%) and particularly among subsets of isolates showing AmpC hyperproduction (10. 9% to 76. 1%) or multidrug resistance (MDR) profiles (27% to 77. 8%). The MICs of ceftazidime-avibactam, in contrast with those of ceftazidime or meropenem, remained at ≤4 μg/ml for a panel of 16 P. aeruginosa PAO1 isogenic mutants expressing multiple combinations of the most relevant β-lactam resistance mechanisms. |
| Grants: | Instituto de Salud Carlos III RD12/0015 Instituto de Salud Carlos III RD16/00016 |
| Rights: | Aquest material està protegit per drets d'autor i/o drets afins. Podeu utilitzar aquest material en funció del que permet la legislació de drets d'autor i drets afins d'aplicació al vostre cas. Per a d'altres usos heu d'obtenir permís del(s) titular(s) de drets. |
| Language: | Anglès |
| Document: | Article ; recerca ; Versió acceptada per publicar |
| Subject: | SDG 3 - Good Health and Well-being |
| Published in: | Antimicrobial Agents and Chemotherapy, Vol. 60, Núm. 10 (October 2016) , p. 6407-6410, ISSN 1098-6596 |
Postprint 16 p, 897.3 KB |